IMR with a Grand Agreement Under Operational Program “Innovation and Competitiveness” (2014-2020)

“Institute for Medical Research” Ltd. (IMR Ltd.) is a beneficiary of the Operational Program “Innovation and Competitiveness“, procedure “Supporting micro and small enterprises to overcome the economic impact of the COVID-19 pandemic” – BG16RFOP002-2.073, co-funded by the European Union through the European Regional Development Fund, with the project “Overcoming the shortage of funding and the lack of liquidity caused by the epidemic outbreak of COVID-19“, under grand agreement BG16RFOP002-2.073-3645-C01.

The project has a total value of BGN 10,000, with BGN 8,500 being financed by the European Regional Development Fund and BGN 1,500 being the amount provided from the national budget.

The project is with duration of 3 months and it started its implementation on 14th July 2020.

The deadline for completion of project activities is 14th October 2020.

The implementation of the project will achieve the main objectives of the procedure, namely:

  • provision of operating capital for IMR Ltd. to deal with the consequences of the COVID-19 pandemic
  • achieving a positive effect for overcoming the economic consequences of the COVID-19 pandemic and stability of job positions in the company.
Съобщение за подписан договор за безвъзмездна финансова помощ по Оперативна програма "Иновации и конкурентоспособност" (2014-2020)

Институт за медицински научни изследвания“ ООД (ИМНИ ООД) е бенефициент по Оперативна програма „Иновации и конкурентоспособност“, процедура „Подкрепа на микро и малки предприятия за преодоляване на икономическите последствия от пандемията COVID-19“ – BG16RFOP002-2.073, съфинансирана от Европейския съюз чрез Европейския фонд за регионално развитие, с проект „Преодоляване недостига на средства и липсата на ликвидност, настъпили в резултат от епидемичния взрив от COVID-19“, по договор BG16RFOP002-2.073-3645-C01.

Проектът е на обща стойност 10 000 лв., като 8 500 лв. е финансирането от Европейския фонд за регионално развитие, а 1 500 лв. е сумата, осигурена от националния бюджет.

Проектът е с продължителност 3 месеца и стартира своето изпълнение на 14.07.2020 г.

Крайната дата за приключване на проекта е 14.10.2020 г.

Реализацията на проекта ще постигне основните цели на процедурата, а именно:

  • Осигуряване на оперативен капитал за „ИМНИ“ ООД за справяне с последиците от пандемията COVID-19
  • Постигане на положителен ефект за преодоляване на икономическите последствия от пандемията COVID-19 и стабилност на работните места в дружеството.

IMR is a company with interests and activities focused on innovations in the field of personalized medicine and biotechnology. Personalized medicine service is focused on modeling, developing, and managing logistics projects and patient support programmes related to companion diagnostics. This involves combining innovative diagnostic technologies with pathological expertise to assess the genetic and molecular characteristics of the tumor in various oncological diseases. The company develops and provides a fully completed diagnostic process to assess the tumor’s molecular (mutation and protein expression) status, including providing the appropriate reagents for each type of diagnosis. In performing patient support programmes a holistic working model is applied – connecting key participants in the healthcare field: patients, diagnosticians, medical specialists, and pharma industry representatives.

Area of expertise

  • EGFR companion diagnostics for patients diagnosed with non-small cell lung cancer (NSCLC)
  • PD-L1 patient support programmes for patients with non-small cell lung cancer and urothelial carcinoma
  • RAS (KRAS, NRAS) companion diagnostics for patients diagnosed with colorectal cancer
Menu